A case report of rhabdomyolysis caused by the use of roxadustat in the treatment caused by renal anaemia
Open Access
- 7 January 2021
- journal article
- research article
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 75 (6) , e14011
Abstract
Case presentation: In this case, we share a case of one of our patients developed rhabdomyolysis after he was administered roxadustat to treat anaemia caused by chronic renal failure.Discussion: More than 1.2 million people died from chronic kidney damage (CKD) globally, in 2017. Anaemia is a common complication of CKD. Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Roxadustat is often used to treat anaemia caused by renal failure. Its adverse effects include high blood pressure, myocardial infarction, heart failure, high potassium, and dizziness; however, there are no reports about rhabdomyolysis associated with roxadustat.Conclusion: Physicians should be alert about the occurrence of rhabdomyolysis when roxadustat is used.Keywords
All Related Versions
This publication has 16 references indexed in Scilit:
- Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practiceCritical Care, 2016
- An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney diseaseExpert Opinion on Drug Safety, 2016
- Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous IronHeart, Lung and Circulation, 2015
- KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKDAmerican Journal of Kidney Diseases, 2013
- RhabdomyolysisChest, 2013
- Intestinal Hypoxia-inducible Factor-2α (HIF-2α) Is Critical for Efficient ErythropoiesisJournal of Biological Chemistry, 2011
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseNew England Journal of Medicine, 2009
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Rhabdomyolysis.2002
- Trends in anemia treatment with erythropoietin usage and patient outcomesAmerican Journal of Kidney Diseases, 1998